Evaluation of a high-throughput peptide reactivity format assay for assessment of the skin sensitization potential of chemicals by Wong, Chin Lin et al.
  
 
Evaluation of a high-throughput peptide reactivity
format assay for assessment of the skin sensitization
potential of chemicals
 Chin Lin Wong1, 2, Ai Leen Lam1, Maree T. Smith1, 2, Sussan Ghassabian1*
 
1Centre for Integrated Preclinical Drug Development, The University of Queensland,
Australia, 2School of Pharmacy, The University of Queensland, Australia
 Submitted to Journal:
 Frontiers in Pharmacology
 Specialty Section:
 Predictive Toxicology
 ISSN:
 1663-9812
 Article type:
 Original Research Article
 Received on:
 23 Sep 2015
 Accepted on:
 26 Feb 2016
 Provisional PDF published on:
 26 Feb 2016
 Frontiers website link:
 www.frontiersin.org
 Citation:
 
Wong C, Lam A, Smith MT and Ghassabian S(2016) Evaluation of a high-throughput peptide reactivity
format assay for assessment of the skin sensitization potential of chemicals. Front. Pharmacol. 7:53.
doi:10.3389/fphar.2016.00053
 Copyright statement:
 
© 2016 Wong, Lam, Smith and Ghassabian. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
 
This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF
and full text (HTML) versions will be made available soon.
 
Pr v
ision
al
Frontiers in Pharmacology | www.frontiersin.org
Prov
ision
al
 1 
 
Evaluation of a high-throughput peptide reactivity format assay for 
assessment of the skin sensitization potential of chemicals 
Chin Lin Wong
1,2
, Ai-Leen Lam
1
, Maree T. Smith
1,2 
and Sussan Ghassabian
1*
 1 
1
Centre for Integrated Preclinical Drug Development, The University of Queensland, St Lucia, 2 
QLD, Australia. 3 
2
School of Pharmacy, The University of Queensland, Woolloongabba, QLD, Australia. 4 
*Correspondence: Sussan Ghassabian, Centre for Integrated Preclinical Drug Development 5 
(CIPDD), The University of Queensland, Level 7, Block 6, Royal Brisbane and Women’s Hospital, 6 
Herston, Queensland, 4029 Australia. 7 
s.ghassabian@uq.edu.au 8 
Keywords: allergic contact dermatitis, Cor1-C420, cysteine, in vitro methods, lysine, peptide 9 
reactivity assay, skin sensitization. 10 
Word count: 5829 words (exclude abstract, figure and table captions and references) 11 
Total number of figures/tables: 13  12 
Prov
ision
al
  Improvement of peptide reactivity assay 
2 
 
Abstract 13 
The direct peptide reactivity assay (DPRA) is a validated method for in vitro assessment of the skin 14 
sensitization potential of chemicals. In the present work, we describe a peptide reactivity assay 15 
using 96-well plate format and systematically identified the optimal assay conditions for accurate 16 
and reproducible classification of chemicals with known sensitizing capacity. The aim of the 17 
research is to ensure that the analytical component of the peptide reactivity assay is robust, accurate 18 
and reproducible in accordance with criteria that are used for the validation of bioanalytical 19 
methods. Analytical performance was evaluated using quality control samples (QCs; heptapeptides 20 
at low, medium and high concentrations) and incubation of control chemicals (chemicals with 21 
known sensitization capacity, weak, moderate, strong, extreme and non-sensitizers) with each of 22 
three synthetic heptapeptides, viz Cor1-C420 (Ac-NKKCDLF), cysteine- (Ac-RFAACAA) and 23 
lysine- (Ac-RFAAKAA) containing heptapeptides. The optimal incubation temperature for all three 24 
heptapeptides was 25°C. Apparent heptapeptide depletion was affected by vial material 25 
composition. Incubation of test chemicals with Cor1-C420, showed that peptide depletion was 26 
unchanged in polypropylene vials over 3-days storage in an autosampler but this was not the case 27 
for borosilicate glass vials. For cysteine-containing heptapeptide, the concentration was not stable 28 
by day 3 post-incubation in borosilicate glass vials. Although the lysine-containing heptapeptide 29 
concentration was unchanged in both polypropylene and borosilicate glass vials, the apparent extent 30 
of lysine-containing heptapeptide depletion by ethyl acrylate, differed between polypropylene 31 
(24.7%) and glass (47.3%) vials. Additionally, the peptide-chemical complexes for Cor1-C420-32 
cinnamaldehyde and cysteine-containing heptapeptide-2,4-dinitrochlorobenzene were partially 33 
reversible during 3-days of autosampler storage. These observations further highlight the difficulty 34 
in adapting in vitro methods to high-throughput format for screening the skin sensitization potential 35 
of large numbers of chemicals whilst ensuring that the data produced are both accurate and 36 
reproducible.   37 
1 Introduction 38 
Allergic contact dermatitis (ACD) is the clinically significant consequence of skin sensitization that 39 
negatively affects approximately 15-20% of the general population (Peiser et al., 2012). At present, 40 
more than 4000 chemicals are linked to induction of ACD in humans (Cahill et al., 2012). A 41 
number of contact allergens, including fragrances, epoxy resin systems, formaldehyde, neomycin 42 
sulphate and nickel sulphate are commonly reported to induce ACD in humans (Cahill et al., 43 
2012;Pesonen et al., 2015).  44 
 45 
Due to the high incident rate of ACD in general population, several animal models such as guinea 46 
pig test (Buehler, 1965;Magnusson and Kligman, 1969;Magnusson and Kligman, 1970;Magnusson, 47 
1980;Magnusson et al., 1979) and murine local lymph node assay (LLNA) (Kimber and Basketter, 48 
1992;Kimber et al., 1994;Kimber et al., 1998;Basketter et al., 1998) have been developed. 49 
However, according to the European Cosmetic Directive (EC1223/2009), the ban of cosmetic 50 
ingredients that were subjected to animal testing was enforced. Moreover, finished cosmetic 51 
products subjected to animal testing were prohibited from being marketed in the European Union 52 
(EU) since 2009 (EU, 2009). Nevertheless, animal testing was still allowed for determining the 53 
complex human health effect. On 11 March 2013, full ban on animal testing for cosmetic purposes 54 
was enforced. Besides, the EU REACH regulation (registration, evaluation, authorization and 55 
restriction of chemicals), EC1907/2006, that came into force on 1 June 2007, provided a strong 56 
imperative for the development and implementation of rapid in vitro screening methods (EU, 2006) 57 
for assessing the skin sensitization potential of chemicals that had not been previously tested using 58 
in vivo methods. Furthermore, implementation of the 3Rs, reduction, refinement and replacement of 59 
animal testing, has driven the need to adopt alternative non-animal skin sensitization screening 60 
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methods. Validated in vitro methods are thus essential for identifying potential skin sensitizers to 61 
prevent ACD (EU, 2009).  62 
 63 
To this end, multiple non-animal testing methods have been developed and evaluated. For 64 
examples, direct peptide reactivity assay (DPRA), human cell line activation test (h-CLAT), 65 
KeratinoSens
TM
 and myeloid U937 skin sensitization test (MUSST) (Ade et al., 2006;Ashikaga et 66 
al., 2006;Bauch et al., 2012;Emter et al., 2010; Gerberick et al., 2004;Sakaguchi et al., 2006;Python 67 
et al., 2007). It was anticipated that in vitro methods would have the ability to assess hundreds of 68 
chemicals concurrently, which is not feasible with methods utilizing the murine LLNA. Although 69 
the mouse LLNA was generally regarded as the ‘gold standard’ test system for identifying skin 70 
sensitization potential of contact allergens (Dean et al., 2001;ICCVAM, 1998;Kimber et al., 71 
1986;Kimber et al., 1989;OECD,2010), the findings did not necessarily always correlate well with 72 
human data due to variability of the test (Basketter et al., 2014; Hoffman et al. 2015;Kolle et al. 73 
2013) and it has been shown that the in vitro tests predict human sensitizing potential better than the 74 
LLNA (Urbisch et al. 2015). This may be due to inter-species differences in anatomy, physiology, 75 
biochemistry and immunology that underpin differential skin responses to various chemicals 76 
between mice and humans (Jamei et al. 2009). 77 
 78 
The DPRA is adopted by the Organization for Economic Co-operation and Development (OECD) 79 
for use in the hazard assessment of chemicals as potential skin sensitizers (OECD, 2012). The 80 
ability of haptens to bind with skin proteins is regarded as the initial key event in skin sensitization 81 
(OECD, 2013). Hapten-protein complexes are formed via covalent modification of amino acid side 82 
chains of proteins. This process, known as haptenation, provides the scientific basis underpinning 83 
the DPRA (Gerberick et al., 2004;Gerberick et al., 2007). Most sensitizing chemicals are 84 
electrophilic in nature, comprising Michael acceptors, SNAr and SN2 electrophiles, Schiff base 85 
formers or acylating agents and so possess the ability to react with the nucleophilic amino acid 86 
residues of skin proteins (Chipinda et al., 2011;Lalko et al., 2012). While lysine- and cysteine-87 
containing heptapeptides more commonly bind covalently to these electrophiles, other residues such 88 
as histidine and methionine also react with haptens (Gerberick et al., 2009). Irreversible covalent 89 
bond formation between haptens and amino acid residues of skin proteins is mimicked in the DPRA 90 
whereby the amount of unreacted exogenous peptide is quantified in the presence and absence of 91 
potential skin sensitizing chemicals (Gerberick et al., 2004).  92 
 93 
The sensitivity and accuracy of various amino acid combinations for simulation of skin proteins in 94 
the peptide reactivity assay have been investigated. Gerberick et al. (2007) proposed the optimum 95 
combinations of the amino acids, glutathione-, cysteine- and lysine-containing peptides for 96 
accurately identifying skin sensitizers. The overarching principle was to eliminate the need for 97 
utilization of a large panel of peptides to ensure reliability of the DPRA for predictive purposes 98 
(Gerberick et al., 2007). Based upon this approach, peptides containing cysteine or lysine, at a 1:10 99 
or 1:50 molar ratio to the test chemicals of interest, respectively, were found to give the best 100 
predictive power for the DPRA (Gerberick et al., 2007). In addition, a synthetic peptide containing 101 
both cysteine and lysine residues (Cor1-C420) which had the added advantage of high aqueous 102 
solubility in reaction buffer, showed high reactivity towards electrophiles (Dennehy et al., 103 
2006;Natsch et al., 2007) and had previously shown promising results for identification of skin 104 
sensitizers (Natsch and Gfeller, 2008). Recently, several improvements for peptide reactivity assay 105 
has been proposed as reviewed in Wong et al. 2015. Due to the nature of chemical reactivity, it is 106 
crucial to incorporate several peptides in the peptide reactivity assay. Nevertheless, it is important to 107 
identify the optimum conditions for each peptide under different circumstances. 108 
 109 
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To minimize inter and intra-laboratory variability in peptide reactivity results, it is important to 110 
ensure that the analytical component of the method is robust, accurate and reproducible in 111 
accordance with criteria that are used for the validation of bioanalytical methods (EMA, 2011;FDA, 112 
2011). Hence, our aims were to develop, optimize and assess the performance of three liquid 113 
chromatography tandem mass spectrometry (LC-MS/MS) analytical methods for quantification of 114 
the concentrations of lysine- and cysteine-containing heptapeptides as well as Cor1-C420 115 
heptapeptides, following their reaction with various representative test chemicals of known skin 116 
sensitization potential. Analytical method validation parameters include accuracy, precision, carry-117 
over, stability of peptides under various incubation temperatures, influence of solvent composition, 118 
autosampler stability over 72 h, and impact of vial materials on assay performance. No direct 119 
comparison with the OECD guideline test or testing of the substances in its minimum performance 120 
standard was carried out in this paper. 121 
2 Materials and methods 122 
2.1 Peptides 123 
Leucine enkephalin acetate salt hydrate (YGGFL) (>98%) was supplied by Sigma-Aldrich 124 
Corporation (NSW, Australia), α-N-acetyl leucine enkephalin (Ac-YGGFL) (>95%), cysteine-125 
containing heptapeptides (Ac-RFAACAA) (>94%), lysine-containing heptapeptides (Ac-126 
RFAAKAA) (>97%) and Cor1-C420 (Ac-NKKCDLF) (>98%) heptapeptides were supplied by GL 127 
Biochem (Shanghai, China). 128 
2.2 Chemicals and Reagents 129 
1-chloro-2,4-dinitrobenzene (DNCB, 99.8%, CAS 97-00-7), cinnamaldehyde (98.4%, CAS 104-55-130 
2), ethyl acrylate (100%, CAS 140-88-5), glutaraldehyde (25%, CAS 111-30-8), isoeugenol (99%, 131 
CAS 97-54-1), methyl salicylate (99.4%, CAS 119-36-8), ammonium hydroxide solution (28-30%), 132 
bovine serum albumin (BSA), DL-dithiothreitol (DTT) and deferoxamine mesylate salt were 133 
supplied by Sigma-Aldrich Corporation (NSW, Australia), high performance liquid 134 
chromatography (HPLC) grade methanol and acetonitrile were supplied by Merck (Darmstadt, 135 
Germany), sodium hydroxide and ammonium acetate were supplied by Chem-Supply (SA, 136 
Australia). Sodium phosphate dibasic and monosodium phosphate were purchased from 137 
ThermoFisher Scientific (VIC, Australia). 138 
2.3 Experimental design 139 
2.3.1 LC conditions 140 
The HPLC apparatus was a Shimadzu chromatographic system. A reversed phase C18 column 141 
(Gemini, 2.0 × 150 mm, particle size 5 μm; Phenomenex, NSW, Australia) and a C18 security 142 
guard column (Gemini, Phenomenex, NSW, Australia) was used for all three heptapeptides. The 143 
column oven and autosampler temperatures were set at 40°C and 4°C, respectively. The injection 144 
volume for all samples was 5 μL. The mobile phase for the Cor1-C420 heptapeptides comprised 145 
mobile phase A (10 mM ammonium acetate, pH 9.5) and mobile phase B (acetonitrile) and the flow 146 
rate was 0.4 m/ min. The mobile phases for the heptapeptides containing cysteine or lysine 147 
comprised mobile phase A (10 mM ammonium acetate, pH 9.5) and mobile phase B (methanol) and 148 
the flow rate was 0.5 mL/min. A stepwise gradient elution program summarized in Figure 1 was 149 
used for each heptapeptide. The acquisition and processing of data were performed using the 150 
Applied Biosystems Sciex Analyst
TM
 software, version 1.6.1. 151 
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2.3.2 MS/MS conditions 152 
MS detection was carried out using an Applied Biosystems Sciex API 3200 triple quadruple MS 153 
equipped with an electrospray ionization source. The highest abundance product ions were selected 154 
for each analyte. Positive ionization mode was chosen for all three heptapeptides and the 155 
corresponding internal standards. The first 5 min of the chromatographic run time were acquired by 156 
the MS. To tune the parameters for the heptapeptides and internal standards, molecular ions were 157 
identified by direct infusion of the solutions of interest and the parameters were automatically 158 
acquired by the Analyst
TM
 software version 1.6.1. Multiple reaction monitoring (MRM) in positive 159 
ionization mode was used to monitor the analytes. The MS parameters for each heptapeptide and 160 
internal standard are listed in Table 1. The chromatographic methods and peak area integrations 161 
were performed using Analyst
TM
 software. 162 
2.3.3 Preparation of peptide standards, calibration curves, quality control (QC) samples and 163 
test compounds with known sensitizing capacity 164 
An eight-point calibration curve for each heptapeptide (Cor1-C420, 5 - 50 µM; cysteine-containing 165 
heptapeptide, 2-100 µM; lysine-containing heptapeptide, 2 - 100µM) was prepared. Duplicates of 166 
three standard QC samples (three times the lower limit of quantitation (LLOQ), 50% of the upper 167 
limit of quantitation (ULOQ), 80% of the ULOQ) were prepared in 0.1 M phosphate buffer (pH7.4) 168 
for Cor1-C420 and the heptapeptide containing cysteine, whereas 0.1 M ammonium acetate buffer 169 
(pH10) was used for the heptapeptide containing lysine. The QC concentrations for Cor1-C420 170 
were 15 µM, 25 µM and 40 µM whereas the QC concentrations for the heptapeptides containing 171 
cysteine and lysine were 6 µM, 50 µM and 80 µM. Test chemicals with known sensitizing capacity 172 
were used as total peptide depletion controls. DNCB (extreme sensitizer), isoeugenol (moderate 173 
sensitizer), cinnamaldehyde (moderate sensitizer) and methyl salicylic acid (non-sensitizer) were 174 
used to assess the stability of the Cor1-C420 and cysteine-containing heptapeptide complexes after 175 
their formation. For the lysine-containing heptapeptide, glutaraldehyde (strong sensitizer) and ethyl 176 
acrylate (weak sensitizer) were used in place of DNCB and isoeugenol. These chemicals were 177 
prepared in acetonitrile; the final percentage of organic solvent (acetonitrile) did not exceed 27% in 178 
the buffer solution. The final reaction volume was 300 µL. The molar ratio of the Cor1-C420 and 179 
cysteine-containing heptapeptides to test chemical in the incubation mixtures was 1:10. By 180 
comparison the corresponding ratio for the lysine-containing heptapeptide and the test chemicals 181 
was 1:50. 182 
2.3.4 Peptide reactivity assessment 183 
After 24 h of incubation, leucine enkephalin acetate salt hydrate (75 µL, 12 µg/mL) or α-N-acetyl 184 
leucine enkephalin (75 uL, 100 µg/mL) as internal standard, was added to the samples prior to a 1 185 
in 20 dilution for the cysteine- and lysine-containing heptapeptides, and a 1 in 8 dilution for Cor1-186 
C420 in 5% acetonitrile in water prior to final analysis. For the cysteine-containing heptapeptide, an 187 
additional step was needed to prevent dimerization of the thiol groups. Specifically, 10 µL aliquots 188 
of 16 mM DTT were added to each diluted sample (final volume 200 µL) followed by incubation 189 
for 30 min at 40°C. 190 
2.3.5 Carry-over assessment and lower limit of quantification (LLOQ) 191 
The LLOQ was assessed using the criteria that the analyte response at the LLOQ must be five times 192 
the baseline noise and it should have an accuracy of ±20% of the nominal concentration (EMA, 193 
2011). The carry-over was assessed by injecting the highest concentration, the upper limit of 194 
quantification (ULOQ) of the analyte followed by a “blank” sample that did not contain the analyte 195 
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of interest, but in the same buffer. The carry-over should not be more than 20% of the LLOQ 196 
(EMA, 2011). 197 
2.3.6 Incubation temperature stability 198 
Calibration curve for all three tested heptapeptides ranging from 2 – 50 µM were incubated at each 199 
of three temperatures, viz 4°C, 25°C or 37°C for a time period of 24 (±1) h. The peptide 200 
concentrations were then assessed as per the methods described in Section 2.3.4. 201 
2.3.7 Adsorption of heptapeptides on polypropylene and glass materials 202 
To assess the extent to which there were adsorptive losses of each of the three heptapeptides of 203 
interest onto the vial materials over time, standard calibration curves, standard QC samples and four 204 
test chemical control samples as described in Section 2.3.3, were prepared in both 96-well 205 
polypropylene plates and borosilicate glass vials throughout the course of experiment. These 206 
samples were incubated at 25°C for a period of 24 (±1) h and were placed in the autosampler and 207 
injected once every 24 h for a 3 day period. The calculated concentrations on days 1, 2 and 3 were 208 
compared with that determined on day 0. Accuracy and precision were calculated from the 209 
duplicates of the QC samples included in each experiment and three independent experiments were 210 
performed. Thus, we had a total of six values for each QC at each concentration (low, medium and 211 
high). 212 
Accuracy = 
𝑁𝑜𝑚𝑖𝑛𝑎𝑙𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛−𝑀𝑒𝑎𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑥100% 213 
Precision = 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑥100% 214 
2.3.8 Stability of the peptide-chemical complexes when stored in autosampler 215 
Standard calibration curves, QC samples and test chemical control samples with known sensitizing 216 
capacity were prepared as per the description in Section 2.3.3. After a mean (±SD) incubation 217 
period of 24 (±1) h at 25°C, the standard calibration curve samples, standard QC samples and test 218 
chemical control samples were placed in the autosampler at 4°C and the stability of the 219 
heptapeptides was monitored for 3 days post-incubation. The back-calculated concentration of the 220 
calibration standards should be within ±15% of the nominal value, except for the LLOQ for which 221 
it should be within ±20% (EMA, 2011). At least 75% of the calibration standards must fulfil these 222 
acceptance criteria for assay validation. QC sample accuracy should be within ±15% of the nominal 223 
values. At least 67% of the QC samples should comply with these criteria. If any of these criteria 224 
was not met, then the analytical batch was rejected. 225 
2.3.9 Linearity 226 
Calibration curve linearity was assessed on three independent experiments. A linear least squares 227 
regression model with 1/x weighting was applied to all calibration curves. The assay range was 228 
considered linear when the back calculated concentrations and the coefficient of variation (CV) of 229 
the calibration standards were within ±15% of the nominal concentrations, except for the LLOQ for 230 
which ±20% was acceptable. The same criteria were applied to the peptide depletion response by 231 
the reference control (i.e. 50 µM Cor1-C420 and 100 µM cysteine or lysine containing 232 
heptapeptides).  233 
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2.3.10 Data analysis 234 
The percent heptapeptide depletion was calculated using Equation 1.  Our findings were compared 235 
with the OECD TG442C for reactivity classification and DPRA prediction (OECD, 2015). The total 236 
depletion of Cor1-C420 and lysine heptapeptide were compared against the values in Table 2 as 237 
Cor1-C420 contains both cysteine and lysine side chains. The total cysteine-containing heptapeptide 238 
depletion was compared against the values in Table 3. 239 
% Depletion =
(
Mean peptide concentration 
in the absence of test chemical
) - (
Mean peptide concentration 
in the presence of test chemical
)
Mean peptide concentration in the absence of the test chemical
×100%    --------- (1) 240 
3 Results 241 
3.1 Chromatography 242 
The MS/MS transitions and optimized MS parameters as well as the chromatograms of the peptides 243 
and internal standards are presented in Table 1 and Figure 2 respectively. 244 
3.2 Carry-over assessment and LLOQ 245 
The percent carry-over was calculated using Equation 2. Carry-over was observed for Cor1-C420, 246 
such that the peak area of the heptapeptide detected in the blank was 10% of the response from the 247 
LLOQ. However, this carry-over was within the acceptance criteria of not more than 20% of the 248 
LLOQ peak area. No carry-over was observed for cysteine- and lysine-containing heptapeptides or 249 
for the internal standard. The LLOQ for Cor1-C420 was 5 µM whereas the LLOQ for both the 250 
cysteine- and lysine-containing heptapeptides was 2 µM. 251 
Carry − over (%)  =
Analyte area detected in the blank sample
Analyte area of LLOQ
×100%    --------- (2) 252 
3.3 Incubation temperature stability 253 
Statistical analysis was performed using repeated measures two-way analysis of variance (ANOVA) 254 
followed by the Bonferroni test to assess the stability of heptapeptides between incubation 255 
temperatures. Statistical analysis was carried out using the GraphPad Prism
TM 
software program 256 
(Version 6.04) and the statistical significance criterion was p<0.05.  257 
 258 
All the standard calibration curves were compared with freshly prepared standard calibration curve. 259 
The standard calibration curves for Cor1-C420 that was incubated at 25°C and 37°C were 260 
significantly different (P<0.05 and P<0.0001, respectively) from that for the freshly prepared 261 
standard calibration curve. This could be due to instability of Cor1-C420 at ambient or high 262 
temperatures. No significance difference was observed for the peptide standards that were incubated 263 
at 4°C for a period of 24 (±1) h (P>0.05). By contrast, the cysteine- and lysine-containing 264 
heptapeptides remained stable for 24 h at 4°C, 25°C and 37°C with no significant difference 265 
(P>0.05) observed for each peptide at the various incubation temperatures. 266 
3.4 Adsorption of heptapeptides onto polypropylene and borosilicate glass vessels 267 
Peptide stability was assessed for Cor1-C420 (at 15, 25 and 40 µM) and for the heptapeptides 268 
containing lysine or cysteine (at 6, 50 and 80 µM) over 3 days in vessels made of polypropylene 269 
and borosilicate glass materials (Table 4). Our data show that the Cor1-C420 concentration for QCs 270 
samples prepared at low, medium and high concentrations remained unchanged in polypropylene 271 
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vials. The accuracy of all three Cor1-C420 QC samples across 3 days was within ±15% of their 272 
respective nominal concentrations. By contrast, all Cor1-C420 analytical batches incubated in 273 
borosilicate glass vials were rejected for days 1-3 as the repeated analyses did not meet the 274 
acceptance criteria as specified in Section 2.3.9. The Cor1-C420 standard curve failed the linearity 275 
assessment and hence the accuracy of the QC samples for this peptide (in glass) was not 276 
determined.  277 
 278 
The concentration of the cysteine-containing heptapeptide QC samples remained unchanged when 279 
stored in vessels made from polypropylene materials throughout the course of the experiment 280 
(Table 4). Additionally, the cysteine-containing heptapeptide QC samples remained unchanged for 281 
up to two days post incubation in borosilicate glass vials. However, the cysteine-containing 282 
heptapeptide standard curve failed the linearity assessment on day 3.  As for the lysine-containing 283 
heptapeptide, the standard curves remained unchanged in vessels made from both polypropylene 284 
(Table 4) and borosilicate glass for up to three days post-incubation.  285 
3.5 Stability of the peptide-chemical complexes when stored in autosampler 286 
The stability of the peptide-chemical complexes stored in HPLC autosampler plates was assessed 287 
using chemicals with known sensitizing capacities, viz DNCB, isoeugenol, cinnamaldehyde and 288 
methyl salicylate, with Cor1-C420 and the heptapeptide containing cysteine (Table 5 - 6). The 289 
corresponding data for glutaraldehyde, cinnamaldehyde, ethyl acrylate and methyl salicylate 290 
incubated with the heptapeptide containing lysine are shown in Table 7. The autosampler stability 291 
of the peptide-chemical complexes was determined to assess the feasibility of injecting a large 292 
number of samples in a single analytical experiment without adversely affecting sample integrity 293 
which would be a requirement for conducting the peptide reactivity assay in high-throughput 294 
format. 295 
 296 
Stability of the peptide-chemical complexes was assessed in polypropylene plates for the Cor1-297 
C420 and cysteine-containing heptapeptides due to the significant losses of both peptides onto glass 298 
materials as reported in Section 3.4.  The total peptide depletion of chemicals with known 299 
sensitizing potential for days 1-3 was compared against those determined on day 0. Following 300 
incubation of each of DNCB and cinnamaldehyde with Cor1-C420, there was a decrease in percent 301 
peptide depletion over the 3-day assessment period (i.e. an increase in peptide concentration). 302 
Importantly, this was not extensive and so the classification of these chemicals with respect to 303 
reactivity class did not change. However, following incubation of isoeugenol and methyl salicylate 304 
with Cor1-C420, the reverse trend was observed such that there was a marked increase in peptide 305 
depletion over the 3-day assessment period (Table 5), that would lead to eventual misclassification 306 
of the reactivity of each of these chemicals. For example, cinnamaldehyde was initially assessed as 307 
having moderate peptide reactivity when assessed on day 0 which was in line with known LLNA 308 
data, with the reactivity gradually decreasing with minimal/no reactivity by 48 h post-chemical 309 
incubation  (day 1). 310 
 311 
Test chemicals incubated with cysteine-containing heptapeptides showed a decrease in peptide 312 
depletion over the 3-day assessment period (i.e. an increase in peptide concentration) for DNCB, 313 
isoeugenol and cinnamaldehyde (Table 6). In particular, the change in peptide depletion over time 314 
resulted in cinnamaldehyde initially being categorized as having moderate reactivity on day 0 but 315 
with this changing to low reactivity from day 1 onwards. 316 
 317 
As there were no losses of the lysine-containing heptapetide in glass or polypropylene vessels 318 
(Section 3.4), the stability of the formed peptide-chemical complexes for the test chemicals, 319 
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glutaraldehyde, cinnamaldehyde, ethyl acrylate and methyl salicylate were assessed using vessels 320 
made from both types of materials. With the exception of cinnamaldehyde, the extent of lysine-321 
containing heptapeptide depletion over the 3-day assessment period remained unchanged for 322 
glutaraldehyde, ethyl acrylate and methyl salicylate in reactions carried out in polypropylene plates 323 
(Table 7).  However, the total lysine-containing heptapeptide depletion by ethyl acrylate (weak 324 
sensitizer) was approximately 20% higher overall for the entire 3-day assessment period when the 325 
reaction was carried out in borosilicate glass vials compared with the corresponding data generated 326 
using polypropylene vials (Table 7).  This apparent difference in the extent of lysine-containing 327 
heptapetide depletion between reactions carried out in polypropylene versus borosilicate glass vials 328 
was not evident for glutaraldehyde, cinnamaldehyde and methyl salicylate as the total lysine-329 
containing heptapetide depletion was similar (±15%) for reactions conducted in both polypropylene 330 
and borosilicate glass vials.  331 
 332 
Overall our present data indicate that the stability of the covalent bonds formed between the test 333 
chemical and heptapeptide of interest, appears to be dependent upon the type of chemical being 334 
assessed as well as the heptapeptides utilized. Although the number of test chemicals assessed was 335 
small, our data suggest that the total elapsed time for conduct of the peptide reactivity assay 336 
irrespective of the heptapeptide used, should not exceed 24 h in order to maximize assay accuracy 337 
which is in line with OECD TG442C (OECD, 2015). 338 
3.6 Linearity 339 
Calibration curves were linear and the slope, y-intercept and regression coefficient (R
2
) were 340 
determined.  Data showing calibration curve linearity for all three heptapeptides using 341 
polypropylene vials are summarized in Table 8 to 10. Our calibration data showed high precision 342 
(<10%) and high accuracy (<10%) between each replicate and days of the assay. The mean slope
 
343 
for Cor1-C420, cysteine- and lysine-containing heptapeptides was 0.0351, 0.0521 and 0.0306 while 344 
the mean R
2
 values were 0.9876, 0.9951 and 0.9958, respectively. 345 
4 Discussion 346 
We used a comprehensive and systematic approach to identify the optimal experimental conditions 347 
for conducting the peptide reactivity assay in 96-well plate format with LC-MS/MS quantification 348 
of the extent of peptide depletion. Specifically, the optimal assay incubation temperature was 25°C 349 
for the three heptapeptides assessed (Cor1-C420, heptapeptides containing cysteine and lysine), as 350 
incubation at 37°C adversely affected Cor1-C420 peptide stability. 351 
4.1.1 Heptapeptides on polypropylene and glass materials 352 
Our data comparing the effects of using a 96-well polypropylene plate relative to borosilicate glass 353 
vials on losses of heptapeptides as well as on the stability of peptide-chemical complexes is an 354 
extension studies described by Natsch et al. 2008 and Roberts et al. 2009, 2014. Importantly, we 355 
found that polypropylene plates were preferable to glass vials in terms of minimizing losses of the 356 
peptides of interest even though glass vials are more commonly used for heptapeptide reactivity 357 
assessments. Our findings extend the existing peptide reactivity assay especially for the example of 358 
the heptapeptide containing lysine-ethyl acrylate complex where total lysine-containing 359 
heptapeptide depletion was ~20% lower when the assay was conducted in polypropylene compared 360 
with glass vials under the same assay preparation conditions. Furthermore, our findings show that 361 
the peptide reactivity assay may not be suitable for screening a large number of chemicals in a 362 
single experiment due to the potential for instability of test chemical-peptide complexes such that 363 
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the peptide concentration may change significantly when stored in an autosampler over a 3-day 364 
period.  365 
 366 
Next, we assessed the impact of the reaction vial materials (polypropylene or borosilicate glass) 367 
used for test chemical incubation reactions on apparent peptide depletion. Our data clearly show 368 
that the Cor1-C420 and cysteine-containing heptpeptides were less affected by polypropylene than 369 
by borosilicate glass. Specifically, the Cor1-C420 and cysteine-containing heptapeptide QCs did not 370 
pass the acceptance criteria for samples processed in glass vials after autosampler storage at 4°C for 371 
periods of 24 h (day 1) and 72 h (day 3) respectively, in contrast to similar samples processed in 372 
polypropylene plates where the QC samples passed the assay acceptance criteria. The use of either 373 
polypropylene or glass materials for the incubation step did not appear to cause non-specific 374 
adsorptive losses of lysine-containing peptide, with the concentrations of all QC samples within the 375 
acceptance criterion of ±15% of the nominal peptide concentrations. However, incubation of ethyl 376 
acrylate (weak sensitizer) with lysine-containing heptapeptide in glass or polypropylene materials 377 
showed that the apparent total lysine-containing heptapeptide depletion was 47.3% or 24.7% 378 
respectively when assessed within 24 h of test chemical addition to the peptide. However, in work 379 
by others, ethyl acrylate gave different percentages of lysine-containing heptapeptide depletion, at 380 
2.1% and 93.7% (Gerberick et al., 2007;Troutman et al., 2011), results that would misclassify ethyl 381 
acrylate as having no/minimal or strong reactivity, respectively. The varying reports on total lysine-382 
containing heptapeptide depletion with ethyl acrylate could be due to different experimental 383 
conditions employed in each case.  384 
4.1.2 Incubation temperature stability 385 
Our present findings on the effects of varying the incubation temperature employed in the peptide 386 
reactivity assay, mimicking the various temperatures used by laboratories globally, on the stability 387 
of the heptapeptides, are also novel. Natsch and Gfeller (2008) used 37°C for incubating various 388 
test chemicals with the Cor1-C420 heptapeptide, whereas Gerberick et al. (2007) and the OECD 389 
guideline, TG442C, recommend a 24 h incubation period at a temperature of 25°C for test 390 
chemicals with cysteine- and lysine-containing heptapeptides (OECD, 2015). Herein, we compared 391 
the effect of these two incubation temperatures (25°C and 37°C) for representative test chemicals 392 
with a range of concentrations of all three heptapeptides, viz, Cor1-C420, cysteine- and lysine-393 
containing heptapeptides with that of freshly prepared samples as the control condition. Our 394 
findings show that an incubation temperature of 37°C may induce loss of Cor1-C420 (Figure 3). By 395 
comparison, a temperature of 4°C did not significantly alter the stability of these three 396 
heptapeptides. A temperature of 25°C was selected as the optimal temperature for subsequent 397 
reactions of test chemicals with each of the three heptapeptides of interest as it had a minimal effect 398 
on the stability of these heptapeptides after 24 (±1) h of incubation.  399 
4.1.3 Stability of the peptide-chemical complexes when stored in autosampler 400 
Chemical reaction of amino acid residues in the heptapeptides with test chemicals involves 401 
irreversible covalent bond formation mimicking the reaction of haptens with amino acid residues of 402 
skin proteins (Gerberick et al., 2004). However, a major challenge with the existing peptide 403 
reactivity assay method is that the stability of the covalent bond formed between heptapeptides and 404 
test chemicals over an extended period, as may be required by high-throughput peptide reactivity 405 
assay screening of large batches of chemicals, is unknown. In our present work, we identified the 406 
maximum period that sample analysis could be performed accurately based upon the stability of the 407 
peptide-test chemical complexes formed. Our data showing that peptide-chemical complex 408 
formation appears to be partially reversible in some instances, are novel. For example, following 409 
incubation of cinnamaldehyde with Cor1-C420 or the cysteine heptapeptide, apparent peptide 410 
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depletion decreased by 5% and 13% respectively by day 3 following initiation of the peptide-411 
chemical reactions. In these instances, the magnitude of these changes did not alter the skin 412 
sensitization classifications. The stability of peptide-test chemical complex formed was assessed 413 
against standard QC samples (without test chemical) stored for the same length of time in the 414 
autosampler at 4°C. As the concentrations of the heptapeptide standard QC samples remained 415 
consistent throughout the course of experiment, this means that any changes observed in apparent 416 
levels of peptide depletion during the 3-day storage period in the autosampler to cause a change in 417 
the chemical reactivity classification of the test chemicals, were not due to instability of the 418 
heptapeptides. Instead, our findings suggest that some of the peptide-chemical complexes were held 419 
together by slowly reversible covalent bonds. Indeed, our findings are aligned with similar findings 420 
in work by others on the kinetic profiles of test chemical-peptide reactions for periods ranging from 421 
5 min to 24 h post-incubation (OECD, 2015;Natsch et al., 2011;Roberts and Aptula, 2014). Our 422 
findings extend previous work to suggest that dissociation of peptide-chemical complexes 423 
formation were not ideal for assessing the peptide reactivity assay.  424 
 425 
Additionally our data indicate that the peptide-chemical complex dissociation rate is chemical-426 
specific. For example, change in apparent peptide depletion was prominent for the Cor1-C420-427 
cinnamaldehyde complex such that during the first 24 h of complex formation, it was classified 428 
correctly as a moderate sensitizer (Gerberick et al., 2005). However, it would have been incorrectly 429 
classified as a non-sensitizer if assessed only on day 3 post-incubation. By contrast, the extent of 430 
peptide depletion determined following incubation of DNCB with the Cor1-C420 differed by ≤5% 431 
over several days of storage at 4°C in an autosampler. For example, cinnamaldehyde was initially 432 
assessed as having moderate peptide reactivity when assessed on day 0 which was in line with 433 
known LLNA data, with the reactivity gradually decreasing with minimal/no reactivity by 48 h 434 
post-chemical incubation  (day 1). In addition, following the incubation of isoeugenol and methyl 435 
salicylate with Cor1-C420, a marked increase in peptide depletion over the 3-day assessment 436 
period, that would lead to misclassification of the sensitizing reactivity of each of these chemicals. 437 
Work involving assessment of the kinetic reactivity profiles of test chemicals with the cysteine-438 
containing heptapeptide showed that the extent of cysteine depletion was dependent upon both the 439 
test chemical concentration and the incubation time, thereby potentially affecting the chemical 440 
potency classification (Roberts and Natsch, 2009;Natsch et al., 2015). Although future investigation 441 
is required to characterize the dissociation rate kinetics of peptide-chemical complex formation for 442 
a broad range of chemicals, we recommend based upon our present findings showing time-443 
dependent changes in apparent peptide depletion by a range of heptapeptides and chemicals, that all 444 
peptide reactivity samples under the experimental conditions chosen here be analyzed within 24 h 445 
of initiation of incubation (at 25°C) between the heptapeptides of interest and a test chemical.  446 
 447 
Our present research highlights the importance of optimizing the reaction conditions in a systematic 448 
and comprehensive manner when evaluating the applicability of an assay such as the peptide 449 
reactivity assay for assessing a wide range of chemical classes. It is crucial to determine the choice 450 
of peptide for peptide reactivity assay as not all sensitizers will react with thiol and/or amine side 451 
chains. For instance, DNCB is thiol reactive and therefore it binds with the thiol side chain of Cor1-452 
C420 and cysteine-containing heptapeptide. Thus in skin cells, DNCB will then activate the nuclear 453 
factor erythroid-derived 2-related factor 2 (Nrf2)-ARE signaling pathway that has a well-known 454 
role in the toxicity pathway activated by skin sensitizers (Natsch, 2010). In contrast, DNCB did not 455 
bind with the amine group in lysine, whereas glutaraldehyde is a lysine reactive compound and so 456 
was suitable for assessment in our lysine depletion assay. Due to the nature of the chemical 457 
reactivity of compounds, peptides with different side chains were included in the peptide reactivity 458 
assay as suggested in OCED TG442C. 459 
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4.1.4 MS/MS Detection 460 
We used MS/MS herein rather than a UV detector as per the OECD TG442C (OECD, 2015), 461 
because MS/MS is more sensitive and selective compared with UV-based detection systems 462 
(Natsch and Gfeller, 2008). In addition, the use of MS/MS allows us to measure the adduct 463 
formation. However, we did not measure the adduct formation in our high-throughput assay due to 464 
different molecular mass for each compound. Use of MS/MS detection enabled us to adapt the 465 
peptide reactivity assay to a smaller reaction volume prepared in 96-well plate format. This 96-well 466 
assay format improved the assay efficiency where it reduces the total analysis time per sample. It 467 
was noted that the total number of substances that can be analyzed in peptide reactivity assay such 468 
as DPRA is limited by the maximum analysis time, i.e. 30 h as mentioned in OECD TG442C 469 
(OECD, 2015). Therefore, the reduction of analysis time for each sample may increase the total 470 
number of substances screened. Although the 96-well plate format provides a crucial step towards 471 
high throughput assay, the existing method could not increase the efficiency of the test considering 472 
that different peptides are required to test independently. A modified version of peptide reactivity 473 
assay where a 96-well plate format with simultaneous readout of all peptides is required to increase 474 
the assay efficiency. However, formal validation would be needed with the new variant of the assay. 475 
5 Conclusion 476 
In summary, we investigated systematically a number of critical aspects of the peptide reactivity 477 
assay that may potentially confound the accuracy and reproducibility of the data generated by the 478 
peptide reactivity assay. Use of three different heptapeptides in the peptide reactivity assay has the 479 
potential to increase assay specificity for detection of skin sensitizers that may bind more favorably 480 
to a particular amino-acid on one peptide rather than another. Hence, optimization of the assay 481 
protocol to provide favorable assay conditions for these peptides and the different chemical classes 482 
being assessed is recommended to ensure that accurate and meaningful data are obtained from the 483 
peptide reactivity assay. More chemical classes will be tested using the suggested parameters in our 484 
future study to determine the suitability of this assay. However, it has been noted that it is 485 
impossible to optimize a general method so that it is suitable for all chemical classes. For example, 486 
our peptide reactivity assay using cysteine- and lysine-containing heptapeptides is not suitable for 487 
assessing sensitizing metals as stated in ECVAM, 2013. Nevertheless, the inclusion of Cor1-C420 488 
heptapeptides in our peptide reactivity assay could not prevent the formation of the coordination 489 
bonds between nitrogen or oxygen atom in the amino acid residues and metal ions. Additionally, 490 
our findings show that conduct of the peptide reactivity assay in large batch sizes may result in 491 
inaccurate data due to instability of chemical bond formation between heptapeptides and some 492 
chemical compounds. These observations further highlight the difficulty in adapting in vitro 493 
methods to high-throughput formats for screening of large numbers of chemicals whilst ensuring 494 
that the data produced are both accurate and reproducible.  495 
6 Abbreviation 496 
ACD: Allergic contact dermatitis 497 
ANOVA: Two-way analysis of variance 498 
BSA: Bovine serum albumin 499 
DPRA: Direct peptide reactivity assay 500 
LLNA: Local lymph node assay 501 
LLOQ: Lower limit of quantification 502 
MRM: Multiple reaction monitoring 503 
OECD: Organisation Economic Cooperation Development 504 
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ULOQ: Upper limit of quantification 505 
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Table 1: MS/MS Conditions for all analytes. 694 
MS Condition Cor1-C420 
Cysteine-containing 
heptapeptide 
Lysine-containing 
heptapeptide 
α-N-acetyl leucine 
enkephalin 
Leucine enkephalin 
acetate salt hydrate 
Collision-induced 
dissociation (CAD) 
gas 
9 5 5   
Curtain gas (CUR) 40 30 30   
Nebuliser 65 55 55   
Ion spray 
temperature (TEM) 
550 550 550   
Collision energy 
(CE) 
45 95 27 63 71 
Collision cell exit 
potential (CXP) 
4 4 4 4 4 
Declustering 
potential (DP) 
41 111 51 51 51 
Entrance potential 
(EP) 
7 11.5 9 9.5 9.5 
MS/MS transition 455.3  120.0 751.3  120.0 389.0  129.3 598.4  120.1 556.2  120.1 
 695 
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Table 2: Percent peptide depletion model based upon cysteine 1:10 and lysine 1:50 (OECD, 696 
2015). 697 
Mean of cysteine and lysine % 
depletion 
Reactivity class DPRA prediction 
0% ≤ mean % depletion ≤ 6.38% No/minimal reactivity Negative 
6.38% < mean % depletion ≤ 22.62% Low reactivity 
Positive 22.62% < mean % depletion ≤ 42.47% Moderate reactivity 
42.47% < mean % depletion ≤ 100% High reactivity 
 698 
Table 3: Percent peptide depletion model based upon cysteine 1:10 (OECD, 2015). 699 
Cysteine % depletion Reactivity class DPRA prediction 
0% ≤ % depletion ≤ 13.89% No/minimal reactivity Negative 
13.89% < mean % depletion ≤ 23.09% Low reactivity 
Positive 23.09% < mean % depletion ≤ 98.24% Moderate reactivity 
98.24% < mean % depletion ≤ 100% High reactivity 
Prov
ision
al
  Improvement of peptide reactivity assay 
20 
 
Table 4: Summary of precision and accuracy in percentage for QC samples of all three heptapeptide in 96-well polypropylene plate assessed at 24 h 700 
intervals for Days 0-3. The accuracy of QC samples was within the acceptance criterion, i.e. ±15% from the nominal concentration. 701 
Heptapeptides  Day 0 (n=3) Day 1 (n=3) Day 2 (n=3) Day 3 (n=3) 
Low Med High Low Med High Low Med High Low Med High 
Cor1-C420 Precision 
(%) 
6.3 6.9 8.5 6.1 7.4 4.7 6.6 11.0 13.1 11.8 13.3 10.4 
Accuracy 
(%) 
1.2 4.5 -2.6 0.1 2.4 -4.6 1.6 4.3 -3.0 -1.5 3.1 -0.6 
Cysteine-
containing 
heptapeptide 
Precision 
(%) 
6.7 5.5 4.6 7.4 7.6 4.5 4.9 3.6 5.4 7.4 3.5 5.6 
Accuracy 
(%) 
-7.3 -4.4 -2.5 6.4 0.3 0.1 -0.7 0.2 -3.0 -4.4 -1.4 -2.3 
Lysine-
containing 
heptapeptide 
Precision 
(%) 
5.9 3.4 6.0 6.0 1.5 6.4 3.7 2.1 9.0 4.8 1.6 11.7 
Accuracy 
(%) 
-7.4 -0.4 -4.4 -4.4 -2.4 -5.7 -6.8 -2.0 -6.1 -5.4 -1.6 -7.3 
 702 
  703 
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Table 5: Percent depletion of the Cor1-C420 heptapeptide incubated with representative test chemicals in polypropylene and borosilicate glass vessels 704 
for a period of 24 (±1) h post-incubation (n=3). Day 0 in the table denotes the first day of sample storage in an autosampler at 4°C. The mean depletion 705 
is calculated based on the data from three replicates from each of three independent experiments. 706 
Test Chemicals Day post 
incubation 
Polypropylene Vessel Borosilicate Glass Vessel 
Mean % depletion (±SD) Classification of Test 
Chemical
1
 
Mean % depletion (±SD) Classification of Test 
Chemical
1
 
DNCB 
(Strong 
sensitiser) 
0 97.14 (±1.0) High reactivity 98.18 (±1.6) High reactivity 
1 93.78 (±0.7) High reactivity N/A   
2 92.86 (±1.5) High reactivity N/A   
3 92.56 (±3.4) High reactivity N/A   
Isoeugenol 
(Moderate 
sensitiser) 
0 64.08 (±1.2) High reactivity 70.07 (±5.5) High reactivity 
1 72.96 (±2.1) High reactivity N/A   
2 80.37 (±6.0) High reactivity N/A   
3 82.07 (±5.0) High reactivity N/A   
Cinnamaldehyde 
(Moderate 
sensitiser) 
0 33.83 (±8.1) Moderate reactivity 35.76 (±5.8) Moderate reactivity 
1 17.66 (±12.7) Low reactivity* N/A   
2 10.47 (±10.9) No/minimal Reactivity*
 
N/A  
 
3 5.21 (±6.3) No/minimal Reactivity* N/A   
Methyl salicylate 
(Weak 
sensitiser) 
0 7.54 (±7.1) No reactivity 8.84 (±5.4) Low reactivity 
1 11.24 (±8.0) Low reactivity* N/A   
2 14.56 (±9.4) Low reactivity* N/A   
3 19.18 (±10.7) Low reactivity* N/A   
*change in reactivity class; N/A denotes the batch failed acceptance criteria 707 
 708 
                                                 
1
 Category of test chemical is based on the OECD TG442C  (Table 2) 
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Table 6: Percent depletion of the cysteine heptapeptide incubated with representative test chemicals in polypropylene and borosilicate glass vessels for 709 
a period of 24 h (±1) h post incubation (n=3). Day 0 in the table denotes the first day of sample storage in an autosampler at 4°C. The mean depletion is 710 
calculated based on the data from three replicates from each of three independent experiments. 711 
Test Chemicals Day post 
incubation 
Polypropylene Vessel Borosilicate Glass Vessel 
Mean % depletion (±SD) Classification of Test 
Chemical
2
 
Mean % depletion (±SD) Classification of Test 
Chemical
2
 
DNCB 
(Strong 
sensitiser) 
0 88.74 (±2.5) Moderate reactivity 85.13 (±1.7) Moderate reactivity 
1 81.36 (±1.0) Moderate reactivity 73.83 (±2.6) Moderate reactivity 
2 75.71 (±1.6) Moderate reactivity 64.09 (±2.7) Moderate reactivity 
3 75.83 (±0.9) Moderate reactivity N/A   
Isoeugenol 
(Moderate 
sensitiser) 
0 32.84 (±7.0) Moderate reactivity 38.77 (±6.9) Moderate reactivity 
1 29.41 (±3.9) Moderate reactivity 35.90 (±0.5) Moderate reactivity 
2 24.54 (±6.2) Moderate reactivity 30.99 (±2.5) Moderate reactivity 
3 28.73 (±7.0) Moderate reactivity N/A   
Cinnamaldehyde 
(Moderate 
sensitiser) 
0 27.40 (±2.9) Moderate reactivity 35.26 (±2.3) Moderate reactivity 
1 22.65 (±0.5) Low reactivity* 24.34 (±7.5) Moderate reactivity 
2 21.10 (±2.8) Low reactivity* 16.82 (±6.7) Low reactivity* 
3 22.66 (±4.0) Low reactivity* N/A   
Methyl salicylate 
(Weak 
sensitiser) 
0 0.50 (±0.9) No/minimal reactivity 5.94 (±3.3) No/minimal reactivity 
1 0.00 (±0.0) No/minimal reactivity 0.45 (±4.5) No/minimal reactivity 
2 0.95 (±1.6) No/minimal reactivity 1.72 (±0.9) No/minimal reactivity 
3 0.84 (±1.5) No/minimal reactivity N/A   
*change in reactivity class; N/A denotes the batch failed acceptance criteria 712 
                                                 
2
 Category of test chemical is based on the OECD TG442C  (Table 3) 
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Table 7: Percent depletion of the lysine heptapeptide incubated with representative test chemicals in polypropylene and borosilicate glass vessels for a 713 
period of 24 h (±1) h post incubation (n=3). Day 0 in the table denotes the first day of sample storage in an autosampler at 4°C. The mean depletion is 714 
calculated based on the data from three replicates from each of three independent experiments. 715 
Test Chemicals Day post 
incubation 
Polypropylene Vessel Borosilicate Glass Vessel 
Mean % depletion (±SD) Classification of Test 
Chemical
3
 
Mean % depletion (±SD) Classification of Test 
Chemical
3
 
Glutaraldehyde 
(Strong 
sensitiser) 
 
0 49.23 (±5.8) High reactivity 55.33 (±4.0) High reactivity 
1 49.03 (±5.2) High reactivity 58.68 (±3.7) High reactivity 
2 49.61 (±5.3) High reactivity 61.98 (±4.8) High reactivity 
3 51.25 (±6.2) High reactivity 66.51 (±7.4) High reactivity 
Cinnamaldehyde 
(Moderate 
sensitiser) 
 
0 7.18 (±6.7) Low Reactivity 9.89 (±6.1) Low Reactivity 
1 4.89 (±5.2) No/minimal Reactivity* 6.28 (±2.4) No/minimal Reactivity* 
2 4.36 (±4.7) No/minimal Reactivity* 4.88 (±1.7) No/minimal Reactivity* 
3 4.08 (±4.6) No/minimal Reactivity* 4.40 (±0.8) No/minimal Reactivity* 
Ethyl acrylate 
(Weak 
sensitiser) 
 
0 24.73 (±9.8) Moderate reactivity 47.28 (±7.7) High reactivity 
1 23.54 (±7.7) Moderate reactivity 43.40 (±5.9) High reactivity 
2 23.68 (±6.4) Moderate reactivity 42.05 (±6.1) Moderate reactivity* 
3 23.42 (±6.6) Moderate reactivity 42.18 (± 6.2) Moderate reactivity* 
Methyl salicylate 
(Non-sensitiser) 
 
0 9.14 (±9.4) Low Reactivity 3.52 (±5.5) No/minimal Reactivity 
1 8.02 (±7.6) Low Reactivity 2.89 (±1.7) No/minimal Reactivity 
2 7.72 (±6.5) Low Reactivity 1.52 (±0.4) No/minimal Reactivity 
3 7.94 (±6.6) Low Reactivity 1.90 (±0.7) No/minimal Reactivity 
*change in reactivity class  716 
                                                 
3
 Category of test chemical is based on the OECD TG442C  (Table 2) 
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Table 8: Calibration curve linearity for the Cor1-C420 heptapeptide (n=3) in 96-well polypropylene plate over 3 days. 717 
 
Mean Measured Concentration (Cm) 
    
Nominal 
Conc. 
(µM) 
Replicate 1 Replicate 2 Replicate 3 
Mean SD 
Precision 
(%) 
Accuracy 
(%) 
Day 
0 
Day 
1 
Day 
2 
Day 
3 
Day 
0 
Day 
1 
Day 
2 
Day 
3 
Day 
0 
Day 
1 
Day 
2 
Day 
3 
5 4.72 5.10 5.20 5.16 4.66 5.09 4.94 5.42 4.96 5.24 5.61 5.77 5.16 0.33 6.4 3.1 
10 9.65 9.74 9.43 9.50 10.0 9.91 9.70 9.14 10.6 10.0* 8.93 8.59* 9.61 0.55 5.7 -3.9 
15 15.4 14.9 14.9 15.6 15.1 14.6 14.2 14.4 14.3 14.2 15.1 14.8 14.78 0.46 3.1 -1.4 
20 20.1 19.8 19.5 20.4 20.5 19.8 21.5 20.4 18.7 21.6 20.0 19.3 20.13 0.83 4.1 0.7 
25 27.0 25.5 25.9 23.4* 26.1 25.2 26.0 25.8 25.8 22.8 22.8 21.9 24.85 1.67 6.7 -0.6 
30 31.4 29.5 30.6 28.7* 30.9 30.9 29.9 29.0* 30.8 30.5* 30.8 29.9 30.24 0.85 2.8 0.8 
40 39.4 41.7 40.8 37.7* 40.8 40.0 41.7 40.6 40.6 41.8 41.0 43.0 40.76 1.33 3.3 1.9 
50 47.3 48.7 48.7 51.9 46.9 49.5 47.1 49.8 49.2 49.8 50.8 51.1 49.25 1.60 3.3 -1.5 
a 0.0580 0.0465 0.0325 0.0336 0.0483 0.0446 0.0453 0.0453 0.0234 0.0165 0.0139 0.0138 0.0351 
   
b -0.0546 -0.1400 -0.1220 -0.1490 -0.0330 -0.1250 -0.1640 -0.2050 -0.0344 -0.0383 -0.0492 -0.0597 -0.0979 
   
R
2
 0.9800 0.9972 0.9830 0.9762 0.9938 0.9980 0.9889 0.9835 0.9881 0.9878 0.9907 0.9839 0.9876 
   
*denotes single data point was used  718 
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Table 9: Calibration curve linearity of cysteine heptapeptide (n=3) in 96-well polypropylene plate over 3 days. 719 
 
Mean Measured Concentration (Cm) 
    
Nominal 
Conc. 
(µM) 
Replicate 1 Replicate 2 Replicate 3 
Mean SD 
Precision 
(%) 
Accuracy 
(%) 
Day  
0 
Day  
1 
Day  
2 
Day  
3 
Day  
0 
Day  
1 
Day  
2 
Day  
3 
Day  
0 
Day  
1 
Day  
2 
Day  
3 
2 2.34 2.11* N/A 2.15 1.84 1.81 N/A 2.03 N/A N/A 1.87 N/A 2.02 0.19 9.6 1.1 
5 4.78 4.76* N/A 4.82 4.90 4.89 N/A 4.99 N/A 5.56* 4.97 N/A 4.96 0.26 5.2 -0.8 
10 9.29 9.06* 8.98 9.62 10.5 10.4 8.91 9.64 10.9 9.99 10.1 10.9 9.85 0.71 7.2 -1.5 
20 18.0 20.4 20.5 19.2 20.7 21.1 21.2 20.3 19.0 18.9 20.6 18.6 19.88 1.07 5.4 -0.6 
30 30.2 29.4* 32.1 30.6 30.8 31.0 31.8 30.5 28.5 29.4 30.7 28.6 30.30 1.14 3.8 1.0 
50 51.2 52.7 52.3 50.5 51.2 51.3 51.3 49.7 49.6 50.5 52.2 50.7 51.10 0.98 1.9 2.2 
80 80.8 80.5 79.0 81.0 78.7 78.2 78.0 79.9 81.2 80.3 79.5 80.9 79.85 1.13 1.4 -0.2 
100 100.4 97.2 97.0 99.0 98.4 98.2 98.7 99.9 101 101 97.1 100 99.06 1.55 1.6 -0.9 
a 0.0291 0.0429 0.0529 0.0376 0.0432 0.0442 0.0547 0.0351 0.0489 0.0755 0.1030 0.0577 0.0521    
b -0.0255 -0.0217 0.1920 -0.0198 0.0165 0.0262 0.2060 0.0031 -0.2070 -0.1580 0.0116 -0.2620 -0.0199    
R
2
 0.9981 0.9903 0.9919 0.9979 0.9968 0.9957 0.9950 0.9993 0.9954 0.9942 0.9944 0.9922 0.9951    
*denotes single data point was used; N/A denotes the points were excluded  720 
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Table 10: Calibration curve linearity of lysine heptapeptide (n=3) in 96-well polypropylene plate over 3 days. 721 
 
Mean Measured Concentration (Cm) 
    
Nominal 
Conc. 
(µM) 
Replicate 1 Replicate 2 Replicate 3 
Mean SD 
Precision 
(%) 
Accuracy 
(%) 
Day  
0 
Day  
1 
Day  
2 
Day  
3 
Day  
0 
Day  
1 
Day  
2 
Day  
3 
Day  
0 
Day  
1 
Day  
2 
Day  
3 
2 1.96 1.93 1.92 1.85 1.87 1.95 1.96 1.97 1.84 1.92 1.86 1.92 1.91 0.05 2.5 -4.4 
5 4.94 5.08 4.98 4.98 4.92 4.92 4.86 4.80 4.98 4.96 4.94 5.00 4.95 0.07 1.4 -1.1 
10 9.89 10.0 9.93 9.98 10.4 10.4 10.2 10.1 10.2 10.0 10.3 9.99 10.13 0.18 1.7 1.3 
20 20.4 20.4 20.8 21.1 20.9 20.4 20.6 21.0 20.8 20.5 20.8 20.3 20.67 0.27 1.3 3.3 
30 30.7 29.8 30.6 31.4 31.0 30.4 30.7 30.8 31.0 30.8 30.8 31.0 30.74 0.38 1.2 2.5 
50 50.7 50.3 50.7 50.9 49.3 48.8 49.2 48.4 51.0 50.6 50.2 51.0 50.09 0.92 1.8 0.2 
80 79.9 79.4 78.7 78.4 77.2 76.5 77.5 78.9 78.7 79.5 79.7 79.5 78.65 1.08 1.4 -1.7 
100 98.6 100 99.4 98.4 101.5 104 102 101 98.4 98.6 98.4 98.4 99.87 1.77 1.8 -0.1 
a 0.0367 0.0332 0.0379 0.0378 0.0251 0.0257 0.0293 0.0302 0.0264 0.0279 0.0289 0.0280 0.0306    
b 0.0037 0.0016 0.0075 0.0098 0.0067 0.0035 0.0013 0.0033 0.0065 0.0043 0.0036 0.0007 0.0044    
R
2
 0.9845 0.9984 0.9990 0.9973 0.9952 0.9968 0.9977 0.9976 0.9958 0.9950 0.9962 0.9959 0.9958    
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10 Figure Legends 722 
Figure 1: Mobile phase gradient elution of (A) Cor1-C420 (B) cysteine- (C) lysine-containing 723 
heptapeptides. 724 
Figure 2: Sample chromatograms of (A) Cor1-C420 (B) internal standard α-N-acetyl leucine 725 
enkephalin (C) cysteine- and (D) lysine-containing heptapeptides. 726 
Figure 3: Area ratio of (A) Cor1-C420 (B) cysteine- and (C) lysine-containing heptapeptides 727 
with respect to internal standard at different incubation temperature. 728 
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